Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596237 | 1.00 | ALOX5 (0.44) | ALOX5KDM4EATMMTORHSD11B1 | |
| SCHEMBL13993964 | 0.79 | PGR (0.45) | ALOX5KDM4EMTORHSD11B1RIPK1 | |
| SCHEMBL13992412 | 0.78 | SLC6A2 (0.42) | — | |
| SCHEMBL29069788 | 0.71 | ATM (0.43) | KDM4EATMRIPK1SMN1; SMN2CNR1 | |
| SCHEMBL18135513 | 0.71 | RIPK1 (0.55) | ALOX5KDM4EATMRIPK1MEN1 | |
| SCHEMBL14200043 | 0.70 | — | — | |
| SCHEMBL408815 | 0.70 | CNR1 (0.49) | HSD11B1RIPK1CNR1CNR2 | |
| SCHEMBL13992420 | 0.70 | — | — | |
| SCHEMBL14519738 | 0.70 | LMNA (0.49) | HSD11B1RIPK1CNR1CNR2 | |
| SCHEMBL12062179 | 0.69 | MTOR (0.56) | ALOX5KDM4EATMMTORRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256638-A1 | PEPTOID NEUTRALIZING AGENTS | UNIV CALIFORNIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256639-A1 | PEPTOID NEUTRALIZING AGENTS | UNIV CALIFORNIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | NEW YORK UNIVERSITY | 2009-12-24 | — | — | US | disclosed |
| WO-2009139922-A2 | PEPTOID COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7462592-B2 | Compositions and methods for polynucleotide delivery | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256638-A1 | PEPTOID NEUTRALIZING AGENTS | SERPINC1, ANTXR2, VIP | ALOX5 2992/4885KDM4E 3695/4885ATM 4378/4885 |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | PEPD, NGLY1, ANPEP | ALOX5 2024/4885KDM4E 4041/4885ATM 4210/4885 |
| US-20140256639-A1 | PEPTOID NEUTRALIZING AGENTS | SERPINC1, ANTXR2, VIP | ALOX5 2992/4885KDM4E 3695/4885ATM 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.